TABLE 2.
Pharmacokinetic parameters of efavirenz and lopinavir
| Drugb | Clasta (μg/ml) | Cmax (μg/ml) | AUCc (h · ng/ml) | t1/2d (h) | Tmax (h) |
|---|---|---|---|---|---|
| Efavirenz | 1.44 (0.510-3.45) | 2.43 (0.957-5.05) | 39.86 (17.92-93.56) | 30.1 (4.7-74) | 10.5 (9.0-17.5) |
| Efavirenz with VPA | 1.32 (0.598-3.81) | 2.03 (1.12-5.73) | 39.00 (18.30-104.09) | 23.4 (5.9-266) | 10.0 (8.5-13.5) |
| Lopinavir | 6.81 (1.64-20.5) | 12.4 (4.60-23.7) | 61.02 (25.24-172.49) | 7.0 (1.9-50.7) | 2.0 (0.0-5.5) |
| Lopinavir with VPA | 10.7 (2.07-17.0) | 16.5 (5.56-22.3) | 106.87 (30.51-142.25) | 7.6 (2.9-32.5) | 1.75 (0.0-7.8) |
a
Clast is the drug concentration drawn at the last time point. Clast is 24 h after dose administration for efavirenz and 8 h after dose administration for lopinavir.
b
The numbers of subjects given 600 mg of efavirenz every 24 h and 400 and 100 mg of lopinavir and ritonavir twice daily were 11 and 8, respectively.
c
Twenty-four-hour and 8-h AUCs at steady state are reported for efavirenz and lopinavir, respectively. The values reported are medians (ranges).
d
t1/2, estimated half-life.